The funded brand of phenobarbitone tablets (15 mg and 30 mg) is changing because the current supplier, API, is closing its New Zealand manufacturing plant. A supplier has applied to Medsafe for marketing approval of their brand of phenobarbitone tablets, and this is being assessed.
Identify patients affected by this change and organise an appointment in June for your patients prescribed phenobarbitone tablets (15mg and 30mg).
Pharmac will fund the patient co-payment for two consultations:
For more information visit the Pharmac website.
Pinnacle will provide a list of affected patients we have been able to identify to practices via HealthLink / PHO folders on Tuesday 23 May. If no list is received, we did not identify patients within your practice on this medication. We strongly recommend you also run a query to ensure all patients have been identified.
An occasional series illustrating the value of using PowerBI to explore your own data. This issue focuses on 'off label' use of melatonin.
Read moreDue to supply issues, weekly dispensing began occurring from 26 January 2023. This limit is in place until 28 February 2023.
Read moreThis programme provides funding for Aclasta infusions for eligible patients. The infusion is to be provided in the community by the patient’s general practice.
View detailsDr Jo Scott-Jones and Dr Dave Maplesden discuss assessing capacity (in activating enduring power of attorney), HPV screening, changes to opioid prescribing and more.